Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Forte Biosciences Inc FBRX

Healthcare Biotechnology
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program... see more

Recent & Breaking News (NDAQ:FBRX)

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Business Wire November 14, 2022

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Business Wire August 17, 2022

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Business Wire August 15, 2022

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Business Wire June 7, 2022

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Business Wire June 7, 2022

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Business Wire May 16, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire September 8, 2021

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile September 6, 2021

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm

Business Wire September 3, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX

PR Newswire September 3, 2021

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Business Wire September 2, 2021

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Business Wire August 16, 2021

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Business Wire August 2, 2021

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Business Wire July 12, 2021

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Business Wire July 1, 2021

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Business Wire May 10, 2021

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Business Wire May 3, 2021

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Business Wire March 24, 2021

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Business Wire March 17, 2021

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Business Wire February 23, 2021